A new study involving the University of East Anglia shows how infections in premature babies could be diagnosed much more quickly.
The research reveals a new way of profiling the microbiome of preterm babies that can significantly speed-up the identification of infections and indicate the best treatments.
The team, led by the Quadram Institute and the Earlham Institute, harnessed next generation sequencing techniques to rapidly and reliably identify the microbes present in a preterm baby’s stool sample that may cause life-threatening conditions such as sepsis or necrotising enterocolitis (NEC).
The method also uncovers the presence of antimicrobial resistance genes, vital information needed to select the most effective treatment.
Research co-author Prof Paul Clarke, from UEA’s Norwich Medical School and a consultant neonatologist and research lead at the NNUH neonatal intensive care unit (NICU) said: “Preterm babies are a group at high risk of dangerous infection. More than 90 per cent of our preterm babies are presently treated with antibiotics, yet in retrospect most did not need them.
“This study is important because it raises the hope that we might soon have available the technology that could help us to discern at a much earlier stage which babies really need antibiotics, and which do not need them.
“This could save many babies from getting antibiotics they did not need and would be an important advance in helping limit antimicrobial resistance.”
Dr Lindsay Hall from the Quadram Institute, said: “Preterm babies are born with underdeveloped gut physiology, immunity, and have an altered gut microbiota, all of which increase risk of life-threatening infections. Time is of the essence in detecting or diagnosing infections.”
“Not only could our approach be more effective, it will also reduce the use of antibiotics and help slow the rise of antimicrobial resistance.”
Using Oxford Nanopore Technology’s MinION portable sequencing device coupled with bespoke software to analyse the sequence data in real time, data can be obtained in under five hours. With current methods taking up to 48 hours, developing this platform for routine use in a clinical setting would allow faster and tailored antimicrobial treatments to be used.
Dr Richard Leggett, Group Leader at EI, said: “With the MinION and our own analysis pipeline, we can go from faecal sample to pathogen and antimicrobial resistance (AMR) profile in just four to five hours. With these kinds of high-risk patients, time is absolutely critical. We can also take advantage of the MinION’s long DNA reads to place AMR genes within host bacteria, enabling better understanding of antibiotic resistance.”
To test their platform, the researchers used the portable MinION to carry out shotgun metagenomics on mock microbial communities. Shotgun metagenomics analyses the genomic sequence from a mixed collection of organisms, in this case 20 different microbes. Having confirmed that the approach using the MinION worked, the researchers progressed to using samples obtained from preterm babies.
To assess how well the platform worked in real life situations, the researchers worked with the NNUH NICU. The clinical research team collected faecal samples from preterm babies, with consent of the parents, as part of a long-term collaboration into the gut health and microbiome in very premature babies.
The method, published in the journal Nature Microbiology, discerned between healthy babies and those diagnosed with NEC or sepsis, with the healthy babies having a strong population of beneficial Bifidobacterium and the others harbouring either E. cloacae or Klebsiella pneumoniae, both of which can cause life-threatening infections.
Crucially, the system facilitates sampling over a period of time, so that changes in the microbiota profile can be monitored. This is very useful for monitoring pathogenic bacteria, but it also lets researchers see how other interventions affect the microbiome over time. For example, it can monitor the effect of antibiotics on the overall microbial profile or measure the effects of probiotic supplementation.
Shotgun metagenomics doesn’t just profile the species diversity. In this study, the researchers were particularly interested in profiling the genes that confer antibiotic resistance in the microbiome – known as the ‘resistome’. Klebsiella in particular is of concern as it is becoming increasingly resistant to multiple antimicrobials. An expansion of shotgun metagenomics could therefore help in surveillance for AMR in these clinical settings.
The development of this platform for rapid, portable microbiota profiling brings its use in a clinical setting closer but more trials at different locations are needed to prove its utility before it can be adopted as a routine diagnostic tool. However, with the fast pace of improvements in the technology, there is clear potential for its deployment to save lives in the clinical setting, and to protect us all from the threat of AMR.
The research was supported by the Biotechnology and Biological Sciences Research Council and the Wellcome Trust.
‘Rapid MinION profiling of preterm microbiota and antimicrobial resistant pathogens’ is published in the journal Nature Microbiology on Monday, December 16, 2019.